Racho Jordanov Co-Founder, President and CEO
Racho Jordanov is a biotech pioneer with more than 30 years of experience building and leading manufacturing operations in development-stage and multi-national biopharmaceutical companies. Mr. Jordanov started his career with Genentech, Inc. in 1981 in San Francisco, where he led the facility start-up and managed on-going commercial manufacturing of the first biotech products to be approved by FDA: insulin and rhGH.
Over his 20-year career at Genentech Mr. Jordanov was at the forefront of innovations in biopharmaceutical manufacturing, from introducing the first processes for monoclonal antibody (mAb) production, to establishing Genentech’s outsourcing capabilities for drug substance, drug product and medical devices, to most recently starting-up new biomanufacturing facilities in the US and Singapore.
In addition to Genentech, Mr. Jordanov led North America manufacturing operations for Serono S.A. (now Merck Serono; Switzerland) and served as the Vice President of Manufacturing and Operations for two California-based biotech start-ups: Cholestech and Telios Pharmaceuticals.
Mr. Jordanov earned his B.S. in Chemical Engineering from the University of California, San Diego, and an M.B.A. from National University in San Diego.
Rose Lin Co-Founder and General Manager, JHL Taiwan
Rose is the co-founder of JHL Biotech, Inc., Cayman as well as the General Manager of JHL Biotech, Taiwan.
Andreas Nechansky, Ph.D. VP of Research and Analytical Operations
Dr. Andreas Nechansky has more than 15 years of experience in the biotech industry and his last position was Chief Operating Officer of a GMP certified analytical service provider. His experience lies within the field of analytical characterization of Biopharmaceuticals and Biosimilars with a strong focus on Bioassays. Andreas’ vision is to build up a unique team by sharing his expertise and knowledge allowing JHL to deliver world-class Biosimilars to the people in need.
Andreas started his career as a postdoctoral fellow at Novartis followed by a position as Research Associate at The Scripps Research Institute. Next he joined the Igeneon/Aphton Biotech company as the Head of Assay Development focusing on developing and clinically profiling monoclonal anti-cancer antibodies. He then co-founded VelaLabs and was responsible for Analytical Operation and Business Development.
Andreas has received a Ph.D. degree in Molecular Biology from the University of Vienna, Austria. He has published papers in the area of allergy and oncology and on analytical characterization of antibodies. He is also the inventor of two patents.
KC Carswell, Ph.D. VP of Process Development
Dr. KC Carswell is the Vice President of Process Development at JHL Biotech. KC joined the company in 2012 as a founding member of the JHL team, and played an important role in the design of JHL’s clinical-scale Taiwan facility and commercial-scale China site.
Prior to joining JHL, KC was a Principal Engineer at Genentech, leading teams in Process Development and Manufacturing Sciences. KC assisted in development of next generation processes for several blockbuster products, and has also lead the transfer of commercial manufacturing processes to new facilities around the world.
Dr. Carswell is a Chemical Engineer and holds a B.S. from The University of Texas and a Ph.D. from Northwestern University.
WeiDong Cui, Ph.D. VP of Manufacturing and Technology
Dr. Weidong Cui has Over 20 years of experiences in Biotechnology Industry, leading teams in Process Development, Manufacturing and CMC Operation of therapeutic and prophylactic biologics.
Dr. Cui joined JHL Biotech from Chempartner, Shanghai, China where he served as an Executive Director/Deputy General Manager. Prior to Chempartner, Dr Cui had worked over 16 years at MedImmune LLC, Gaithersburg, MD, USA and played a number of leadership roles in Process Development, Manufacturing Sciences and Commercial Manufacturing Operation.
Dr. Cui received a Ph.D. degree in Microbiology from Syracuse University and was a postdoctoral fellow in Pharmaceutical Chemistry at University of California, San Francisco, CA.
Sohail Qureshi VP of Quality
Sohail Qureshi is the Vice President of Quality at JHL Biotech. Sohail has over 20 years cGMP quality leadership experience in biotechnology industry including development and deployment of quality systems and business processes to ensure regulatory compliance and business needs.
Sohail is a certified ISO 9001:2008 and cGMP lead auditor.
Prior to joining JHL, Sohail has worked at Genentech (San Francisco and Singapore), Imclone/Eli Lilly, MONSANTO, and NovoNordisk/Novozymes (North America) within various quality functions including both QA and QC.
Peter Pang, Ph.D. VP of Regulatory Affairs and Clinical Operations
Dr. Pang joined JHL Biotech in November 2014, he now serves as the Vice President of Regulatory Affairs and Clinical Operations. Prior to joining JHL Biotech in 2014, Dr. Pang was Director, Regulatory Affairs at 159 Antiaging Center Ltd, a biotech company developing cell based regenerative therapy. From 2008 to2013, he was General Manager, Scientific Affairs and later Assistant Director, Regulatory Affairs at New B Innovation Ltd where he directed the nonclinical development and regulatory programs for human and veterinary oxygen carrying therapeutics. Dr. Pang received his Ph.D. in Chemical Engineering and B.A. Sc. in Chemical Engineering/Chemistry from the University of British Columbia. He then joined the Michael Smith Laboratories, the University of British Columbia as a Postdoctoral Fellow. Dr. Pang has over twelve years of diverse drug development and regulatory experience.
Allen Ho, Ph.D. Sr. Director of Regulatory Technical CMC
Dr. Ho joined JHL in Sep 2016 as Senior Director, Regulatory Technical CMC. Prior to joining JHL, Dr. Ho was Director of Recombinant Protein Therapeutics in Pharmaessentia. He was a cross-functional team leader to deliver CMC document for IND and MAA filing. Allen started his career as postdoctoral researcher at Academia Sinica, Taiwan and moved to Taiwan-France joint integrated structural biology project in Strasbourg, France. Dr. Ho received his Ph.D. in Chemistry from National Cheng-Kung University, Taiwan. He published papers in biophysical and biochemical characterizations of proteins.
Fred Shaw Director of Engineering Projects and Taiwan Validation
Fred Shaw is the Director of Engineering Projects and Validation at JHL Biotech Taiwan. Prior to joining JHL, he was the Deputy Director, Engineering Division of L & K Engineering Co., Ltd., which is an expert of Cleanroom and Facility Provider for hospital and pharmaceutical plants. He has more than 40 years of experience in Engineering, Construction and Project Management of local and overseas projects within large Consultant Companies in Taiwan including CTCI Corporation and L & K Engineering Co., Ltd.
Fred holds a M.S. degree in mechanical engineering from Marquette University, Wisconsin and is a registered professional mechanical engineer in Taiwan.
WeeLim Goh Director of Facility Inspection and Taiwan Engineering
WeeLim Goh is the Director of Facility and Engineering at JHL Biotech. In this role, he is responsible for JHL’s corporate facility and engineering in support of manufacturing. Prior to joining, he was Senior Manager - Engineering and Maintenance at Roche Singapore.
WeeLim has over 17 years of Engineering and Maintenance leadership experience in the life science industry. He has held various positions of increasing managerial responsibilities in different Biotechnology and Pharmaceutical companies including Merck Shape & Dohme, Edwards Lifesciences and Roche.
He received his B.Eng. degree with honors in Mechanical Engineering from Loughborough University of Technology and his M.B.A. degree from The Adelaide University.
Jill Liu, CPA(US) CIA MBA LLM Financial Controller
Jill is the Financial Controller at JHL Biotech. Since year 2015, Jill has been working in JHL on the areas of internal control, financial reporting, monitoring and management.
Jill started her career from a financial auditor and internal control consultant in PriceWaterhouseCoopers. She has also obtained finance insight from working in BNP Paribas. Since year 2003, Jill has worked for various start-ups, including Cal-comp, an IT hardware manufacturer public listed in Bangkok, and Rockmobile, a service web/mobile service provider, at financial leadership roles.
Jill is a certified public accountant registered with Washington State USA. She earned a master degree in business administration at School of Management, Bradford University, UK.
Zack Zheng, Ph.D. VP of Process Development (Wuhan)
Dr. Zheng is the VP of Process Development of JHL Xikang (Wuhan) site in China. Prior to joining JHL, Zack was the VP of Jecho BioPharm, and VP and Co-founder of DZM Biotech. Previously, he held several senior positions in Pfizer, Wyeth, MedImmune with increased responsibility.
Zack has more than 16 years of broad industrial experience from process development and scale up, to cGMP manufacturing, as well as analytical development for different molecules including monoclonal antibodies, therapeutic proteins and vaccines in US and China. He holds a B.Sc. in chemistry from Beijing Normal University, a Ph.D. from Nankai University, and was a postdoctoral fellow in chemistry and biochemistry at University of Delaware.
James Chang Senior Director of Quality Assurance (Wuhan)
James Chang is the Director of Quality Assurance (QA) at JHL Biotech’s Wuhan site.
James has over 20 years of quality, manufacturing, validation and general management experience in the pharmaceutical industry. He has worked within various companies including Schering-Plough, Merck Sharpe & Dohme, Pfizer and Novartis in both Singapore and China.
James received his B.Eng. (Hons) in Chemical Engineering from National University of Singapore.
Michael Xie, Ph.D. Senior Director and Head of Quality Control (Wuhan)
Michael Xie is the Senior Director and Head of Quality Control at JHL Wuhan (XiKang).
Michael had years of experience as a leader in quality control and analytical development of monoclonal antibodies (mAbs), glycoprotein therapeutics, and related biological field; he also had extended experience in leading team and supervision of scientists, lab equipment and projects, including helped set up GMP protein analytical labs and GLP forensic testing labs.
Prior to joining JHL, Michael was Executive Director, Protein Analytics and QC at Suzhou Suncadia Biopharmaceuticals, a subsidiary of Hengrui Medicine; and before that he was Senior Director, Protein Analytical Sciences at WuXi AppTec Biopharmaceuticals. Before returning to China at 2014, Michael had tremendous US experience in biotech field as he was Director, Protein Analytics and Characterization at KPI Biopharma and senior scientist experience at Waters Corporation and University of Minnesota.
He graduated with Ph.D. of Chemistry at Trinity College, University of Dublin in Ireland.
Henry Wu Director of Corporate Projects and Engineering and Validation (Wuhan)
Henry Wu joined JHL in July 2016 as the Director of Corporate Projects, Wuhan Engineering and Validation.
Henry has extensive engineering and project management experience in the pharmaceutical industry, focused on project and process engineering, system retrofitting, facilities management, and scheduling. He is also experienced in process/plant engineering from API (media processing, fermentation, purification) to filling & freeze drying (finishing). Additional skills and experience in Supply Chain Management and tech transfer projects.
Before joining JHL, Henry worked for 3 years as Project Manager of the Project Engineering Group with Bayer Healthcare in California. Prior to Bayer Healthcare, he worked for Genentech and has over 20 years of experience in pharmaceutical industry.
Henry received a B.S. of Chemical Engineering from San Jose State University and B.S. of Biochemistry from University of California, Riverside.